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Genetic Causes of Human NK Cell 
Deficiency and Their effect on  
NK Cell Subsets
Emily M. Mace* and Jordan S. Orange*
Center for Human Immunobiology, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, USA
Human NK cells play critical roles in human host defense, particularly the control of viral 
infection and malignancy, and patients with congenital immunodeficiency affecting NK 
cell function or number can suffer from severe illness. The importance of NK cell function 
is particularly underscored in patients with primary immunodeficiency in which NK cells 
are the primary or sole affected population (NK cell deficiency, NKD). While NKD may 
lead to the absence of NK cells, we are also gaining an increasing appreciation of the 
effect that NKD may have on the generation of specific NK cell subsets. In turn, this 
leads to improved insights into the requirements for human NK cell subset generation, as 
well as their importance in immune homeostasis. The presence of inherently abnormally 
developed or functionally impaired NK cells, in particular, appears to be problematic in 
the way of interfering with normal human host defense and may be more impactful than 
low numbers of NK cells alone. Here, we review the known genetic causes of NKD and 
the insight that is derived by these into the requirements for human subset generation 
and, by extension, for NK cell-mediated immunity.
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iNTRODUCTiON
While human NK cells and NK cell subsets have been well described, understanding the true physi-
ologic role that they serve in humans has been difficult. The heterogeneity of NK cells as a result of 
both genetic and environmental diversity, as well as the divergence in phenotypic markers between 
mouse and man has made advances in the field incremental. An important tool in the understanding 
of human NK cells and NK cell subsets has been the discovery of human inborn genetic immu-
nodeficiency diseases (primary immunodeficiencies) that affect the generation or homeostasis of 
NK cells or specific NK cell subsets as well as those that affect NK cell function. There are over 300 
genetic deficiencies of human immunity, and nearly 50 are known to have at least some impact on 
NK cells. This latter category has been reviewed by a number of authors in recent years (1–4). Five of 
these primary immunodeficiencies, however, may have their primary impact upon NK cells and are 
known as NK cell deficiency (NKD) (these are summarized in Table 1). These have provided insight 
into the requirements for human NK cell maturation, the importance of the successful execution of 
NK cell development, and the overall value of certain NK cell functions. Here, we will describe recent 
advances in our understanding of the importance of human NK cell subsets and NK cell function 
as informed by NKD.
TABLe 1 | Human NK cell deficiencies and their effect on NK cell subsets, function, and proliferation.
NKD 
type
Gene inheritance NK cell 
number
NK cell lytic  
function
NK cell  
proliferation
CD56dim CD56bright Associated immune phenotype Reference
cNKD GATA2 AD or 
spontaneous
Normal 
or ↓
↓ ND Normal or ↓ Absent/
severely ↓
DC cytopenia, B cell lymphopenia, 
monocytopenia, CD4 
lymphocytopenia, neutropenia  
(all variable across reported cases)
(33, 37–39)
cNKD IRF8 AR ↓ ↓ ND ↓ Normal/↑ Mild DC phenotype (66)
cNKD MCM4 AR ↓ ↓ ↓ ↓ Normal/↑ None (53, 54)
cNKD RTEL1 AR ↓ ↓ Normal ND ND None in NKD patient reported (60, 61)
fNKD FCGR3A AR Normal ↓ ND Normal Normal None (71)
AR, autosomal recessive; AD, autosomal dominant; ND, not done.
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HUMAN NK CeLL SUBSeTS
Human NK cells in peripheral blood are broadly classified as being 
CD56+CD3− and generally comprise 1–17% of mononuclear cells 
within peripheral blood of healthy adults (5). They are found 
primarily in two broadly defined phenotypic subsets, namely the 
CD56bright and CD56dim subsets, with the CD56dim subset being 
the predominant one in peripheral blood. While the basis for 
this stratification is the surface density of CD56 itself, each is 
a distinct functional subset with its own repertoire of markers 
that represent its capabilities. CD56bright NK cells are broadly 
defined as being the potent producers of cytokines, whereas the 
CD56dim subset is the classical mediator of contact-dependent 
cytotoxicity, both natural and antibody-dependent. However, 
exceptions to these rules exist, and there is evidence that both 
subsets can perform the tasks commonly attributed to the other 
(6, 7). In addition, there are several well-defined functional and 
phenotypic intermediaries between the two, as well as several 
subsets that are specifically expanded after infection or other 
immune stimulation. These include the CD56neg subset, which is 
commonly found expanded in patients with HIV and HCV (8, 9). 
It should be noted that these cells are not truly CD56 negative, 
although the expression of CD56 on them is significantly lower 
than that of the CD56dim subset. They retain expression of CD16, 
killer cell immunoglobulin receptors (KIR, CD158 family), and 
CD57 and are generally thought to be terminally differentiated or 
exhausted cells (10). An additional important subset expanded in 
disease is the adaptive NKG2C+ population expanded following 
certain viral infections, particularly CMV (11–13), but also in 
cases of reinfection of CMV seropositive individuals by hantavi-
rus (14), HIV (15, 16), Epstein–Barr Virus (17), Hepatitis C Virus 
(18), and Chikungunya virus (19). Further studies have revealed 
distinct subsets associated with the generation of adaptive NK 
cells following CMV infection. These cells are high affinity IgE 
receptor (FcɛRIγ)-deficient and express low amounts of Syk and/
or EWS/FLI1-activated transcript 2 (EAT2) (20, 21). Further 
adaptation of the NK cell repertoire occurs with epigenetic silenc-
ing of promyelocytic leukemia zinc finger (PLZF) (22). There is 
also remarkable diversity generated by both environmental and 
genetic factors within the human population as a whole with 
regards to NK cell receptor expression and functional potential 
(23, 24).
The relationship between CD56bright and CD56dim subsets is 
not entirely clear, although it is thought that they represent the 
two terminally mature populations of NK cells derived from less 
mature NK cell precursors. There are oft-cited lines of evidence 
suggesting that CD56bright NK cells are the direct precursors of 
the CD56dim subset, namely the longer telomeres in CD56bright 
NK cells (25), their earlier regeneration after HSCT (26), and the 
generation of CD56dim NK cells from CD56bright cells in certain 
experimental systems (27–29). The expression of CD56 on NK 
cells is unique to human and non-human primate systems, which 
has made the study of this specific aspect of NK cell develop-
ment difficult to model prior to the advent of humanized mouse 
models. The use of such humanized mice, in which human NK 
cells develop in a rodent system, showed that CD56bright NK cells 
give rise to CD56dim cells (29); however, a recent study using 
genetic bar coding of NK cell lineages in rhesus macaques was 
indicative of the two subsets having distinct ontologies (30). 
Ultimately, answering this important question for NK cell biol-
ogy will require a dissection of the mechanism that drives NK 
cell development using a satisfying human model. The study of 
primary human NKDs that affect NK cell subset generation are 
an informative tool in this endeavor, specifically for identifying 
novel requirements for the generation and homeostasis of human 
NK cell subsets (discussed further below). While complex, these 
disorders also provide insight into the functions of particular NK 
cell subsets in humans, as well as the overall value of NK cells in 
human host defense.
CLASSiCAL NKD
Classical (c)NKD refers to NKD as a result of absent or pro-
foundly decreased CD56+ CD3− NK cell number, specifically 
defined as ≤1% of peripheral lymphocytes (3, 31). As a result, 
these are disorders in which overall NK cell development and/
or homeostasis is impaired. Recent studies enabled by next 
generation sequencing techniques have identified genetic causes 
for previously described but unidentified cNKD. In combina-
tion with these genetic advances, we have also seen an increase 
in our understanding of NK cell subsets and the cell biological 
tools used to evaluate them. As a result, we can now appreciate 
that cNKD also includes cases in which human peripheral blood 
NK cell subsets are selectively underrepresented or absent. Thus, 
while cNKD has been historically used to define individuals 
with very low percentages of NK cells among peripheral blood 
lymphocytes, we would propose that this definition be expanded 
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to include any example of impaired development or survival lead-
ing to the gross underrepresentation of a major NK cell subset. 
We would also argue that abnormally developed NK cells or the 
absence of particular NK cell subsets in the presence of others is 
far more relevant to host defense than simply having low overall 
numbers of NK cells.
To date, there are four genetically defined reported causes of 
cNKD, and of these at least three (MCM4, GATA2, IRF8) contain 
an aspect of subset aberration, in addition to NK cell numbers 
ranging from the low end of normal to undetectable. The fourth 
(RTEL1) presents information too limited to make a definitive 
statement other than there being underrepresented NK cells 
seemingly in isolation from other immune defects. In some cases, 
namely GATA2 deficiency, a single gene defect may account for a 
widely variable clinical phenotype with regards to NK cell num-
ber. This likely is related to the effect of specific mutations but 
may also be reflective of innate plasticity of NK cell numbers and 
subsets over time, in even healthy individuals, and the infectious 
history of the patient (5, 23, 24).
GATA2
GATA2 deficiency is the genetic lesion behind the most fre-
quently cited case of classic NKD in the literature. A 13-year-old 
girl, originally presenting with varicella pneumonia, was found 
to have decreased NK cell number and function in the presence 
of T cell and B cell function (32). In addition to VZV, CMV and 
HSV infections followed, and she ultimately developed aplastic 
anemia and died during the course of hematopoietic stem cell 
transplantation (32, 33). Posthumous sequencing from a cryo-
preserved T cell line identified a pathogenic frameshift GATA 
mutation (c.1025_1026insGCCG; p.A342GfsX41), confirming 
GATA2 haploinsufficiency as the cause of her disease (33). 
GATA2 haploinsufficiency was also described as a cause of DC 
and monocyte deficiency (MonoMAC, DCML) by independent 
groups in 2009, and NK cell cytopenia was noted as a feature 
of disease (34–36). More detailed phenotyping has revealed 
that there is variation in the NK cell number in these patients, 
with many of them having less than 1% NK cells within their 
lymphocyte population. However, there is a substantive range 
in NK cell number, with some patients having NK cells within 
the normal range of healthy donors. Despite the presence of NK 
cells in some patients, a consistent and notable feature of GATA2 
deficiency is the absolute loss of the CD56bright NK cell subset (33). 
Originally described in a cohort of eight patients, this has since 
been reported by other groups (37, 38) and is a consistent feature 
of the >30 patients that we have studied with GATA2 deficiency 
and accompanying infectious history or hematologic disease.
While it is difficult to estimate the prevalence of GATA2 
mutation within the general population, the report of a cohort 
of 57 patients, of which 82% have clinically detected NK cell 
lymphopenia and 70% have severe and early onset viral infection 
suggestive of NK cell dysfunction, is the largest group of NKD 
patients that we are aware of (39). This suggests it is perhaps the 
most common NKD, as this cohort alone significantly outnum-
bers those reported with RTEL1, MCM4, IRF8, and FCGR3A 
mutations. Furthermore, GATA2 is also the only gene associated 
with NKD that is autosomal dominant (via haploinsufficiency) 
and the only for which spontaneous cases have been reported (35, 
36), thus supporting the statement of commonality from a genetic 
standpoint as well.
GATA2 deficiency is complex as it can be a multi-syndromic 
disease affecting multiple organs and presenting in multiple dif-
ferent ways. Patients can be susceptible to atypical mycobacterial 
infections, fungal infections, and severe and recalcitrant viral 
infections. Interestingly, there is a seemingly progressive nature 
of the disease, with many patients presenting in young adulthood 
and some even later in life. The range of clinical presentations 
and natural history has been well described elsewhere (39). 
Interestingly, one of the earliest clinical features to appear is a 
susceptibility to HPV disease, which could point to a role for 
NK cell-mediated defenses. In addition to immune deficiency, 
GATA2 deficiency is a cause of familial bone marrow failure (40), 
and a recent study of over 400 children and adolescents revealed 
GATA2 mutation to be the most common germline mutation 
leading to myelodysplastic syndrome in children and young 
adults (41). While this group did not specifically examine NKD 
in their cohort, they report half of their patients to have immu-
nodeficiency, suggesting that the high rates of NK cell cytopenias 
reported by Spinner et al. (39) are likely present in this group.
However, there are some notable aspects of GATA2 deficiency 
with regards to NK cell biology. While other NK cell deficien-
cies have been reported as affecting the frequency of subset 
distribution (particularly MCM4, described below), the loss of 
the CD56bright NK cell subset is as near to absolute as has been 
described. The mechanism by which GATA2 regulates the 
development or maintenance of the CD56bright NK cell pool is not 
understood. GATA2 is a zinc finger transcription factor that is 
required for embryonic hematopoiesis, and maintenance of the 
stem cell pool in adults (42, 43) and GATA2 haploinsufficiency 
can also lead to loss of dendritic cell subsets and B cell cytopenias. 
Therefore, given its important role in stem cell maintenance and 
hematopoiesis, GATA2 deficiency may affect multiple immune cell 
lineages, which are again highly variable from patient to patient. 
In vitro differentiation of NK cells from patient hematopoietic 
stem cells leads to aberrant NK cell development, suggesting that 
NKD is cell intrinsic in these patients (33). However, given the 
interdependence on particularly NK and DC cross talk, it is likely 
that loss of other subsets affects NK cell numbers and functions 
in these patients, although this has not been explicitly studied. 
Immune manifestations include susceptibility to mycobacterial 
disease, frequently M. avium and M. kansasii, susceptibility to 
fungal infection, and severe herpesviral infections (39). An 
increased rate of malignancy may be in part due to viral infection 
as this includes increased rates of cervical cancer in young women 
potentially attributable to human papillomavirus infection. Less 
common clinical symptoms include miscarriage, solid organ 
tumors, and lymphedema (Emberger’s syndrome) (39).
Due to the requirement for GATA2 in renewal of the adult 
stem cells, it is thought that depletion of the stem cell pool leads 
to subsequent lymphopenia, and in vitro differentiation experi-
ments demonstrate an NK cell intrinsic role for GATA2 through 
the phenocopying of the CD56bright NK cell subset loss in NK 
cells derived from patient CD34+ HSC (33). Whether GATA2 
is required for the generation or homeostasis of CD56bright NK 
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cells, or whether the defect arises earlier in lineage commitment, 
remains to be determined. GATA2 is highly expressed not only 
in CD34+ HSC, but also across a range of lineages including 
monocytes, monocyte-derived dendritic cells, B cells, and mature 
NK cells, as well as the common myeloid precursor (44–46). 
Conditional deletion of Gata2 in mice has recently demonstrated 
its requirement for DC differentiation from lineage negative 
precursors (47). Interestingly, this is at least partially through 
repression of genes that control T cell and ILC lineages, including 
Tcf7, Eomes, and Gata3. Direct binding of the Gata3 promoter by 
Gata2 in common myeloid progenitor cells suggests that these 
two transcription factors may play a role in tuning fate decisions 
similar to the well described GATA switch that occurs between 
GATA1 and GATA2 and is independent of transcription factor 
expression (47, 48).
This particular deficiency also allows for one to hypothesize 
regarding potential contribution of NK cells to human host 
defense. Given that some GATA2 deficiency patients lack only the 
CD56bright subset, it could speak to an important role for human 
NK cell-derived cytokine production specifically in the defense 
against HPV and/or herpesviruses. As there is strong animal 
model support for this role (49–51), the connection is at least 
plausible. It is not possible, however, to draw a direct connection 
as there is the variable impact upon other elements of innate 
immunity in these patients as discussed above. Furthermore, 
there are also those GATA2 deficiency patients that essentially lack 
NK cells altogether as well as those who have CD56dim NK cells. 
As deficient natural cytotoxicity is a conserved clinical hallmark 
of GATA2 deficiency (32, 33), this leaves open the contribution of 
contact-dependent cytotoxicity as the critical NK cell-mediated 
component of viral control. Thus, while GATA2 deficiency pro-
vides both insights and compelling leads, further work needs be 
done to formally attach a specific role to NK cell defenses through 
this disorder.
MCM4
Mutations in minichromosomal maintenance complex member 
4 (MCM4) were described in 2012 as a cause of NKD accom-
panied by adrenal insufficiency, developmental delay, and short 
stature in a population of endogamous Irish travelers (52–55). 
Notably, patients in this cohort had increased susceptibility to 
viral infection, including cytomegalovirus, and malignancy 
(52–54). An initial description selective NKD (52) was followed 
by a genetic diagnosis of splice-site mutations in MCM4 and 
more detailed analysis of the NK cell phenotype (53, 54). MCM4 
patients were the first to have demonstrated heritability to NKD 
and were the first listed in the Online Mendelian Inheritance in 
Man database as such (OMIM# 609981). Patients with MCM4 
mutation have decreased frequency of CD56dim NK cells and, as 
a result, a relative overrepresentation of the CD56bright subset with 
an overall decrease in absolute numbers of NK cells (53). Careful 
analysis of both NK cells and fibroblasts from six patients in the 
Irish traveler cohort yielded novel insight into both NK cell biol-
ogy and the role of the MCM complex in NK cell homeostasis 
and human disease. Specifically, CD56bright NK cells from patients 
had decreased rates of proliferation and impaired terminal 
maturation. This likely accounts for the severe viral susceptibility 
in these patients as they are lacking the more mature subset of 
NK cells and have at least some instability within the CD56bright 
population (53).
Why does MCM4 mutation exert such a specific, profound 
effect on NK cell maturation and function? MCM4, along with 
MCM2–7, MCM10, and GINS1 form a highly conserved com-
plex that plays a critical role in the initiation and elongation of 
eukaryotic DNA replication (56, 57). Embryos from the Mcm4 
knockout mouse do not survive implantation, and mice carry-
ing the hypomorphic Chaos3 mutation affecting Mcm4 have 
genomic instability reminiscent of that found in MCM4 patients 
(58). Careful analysis of the patients’ fibroblasts showed normal 
MCM2–7 complex formation and DNA-binding but impaired 
DNA replication and, subsequently, cell cycle arrest (53). Genomic 
instability frequently accompanies impaired replication, and this 
is also the case in MCM4 patient fibroblasts, which had increased 
rates of chromosomal breakage (53). Interestingly, accompany-
ing the decrease in NK cell number and specific decrease in 
frequency of CD56dim NK cells, patient NK cells had impaired 
proliferation in response to cytokine stimulation and increased 
rates of apoptosis (53).
The apparent role of MCM4 in the generation of CD56dim NK 
cells is not fully understood; however, it may speak to a previously 
hypothesized requirement for homeostatic proliferation, specifi-
cally in the CD56bright subset, leading to generation of the CD56dim 
subset. This model was originally proposed based on differential 
rates of apoptosis and proliferation detected in CD56bright and 
CD56dim NK cells in peripheral blood (59). The rapid proliferation 
of peripheral blood CD56bright cells with little apoptosis suggests 
that this subset either becomes recruited to tissue or generates 
the CD56dim subset, as substantiated by mouse xenograft stud-
ies (29). Should the latter be the case, the loss of CD56dim NK 
cells in MCM4 patients could be explained by the inability of 
the CD56bright NK cells to successfully undergo this proliferative 
burst and effectively generate CD56dim NK cells. Clearly, MCM4 
deficiency raises many important new questions in NK cell biol-
ogy, and answers will undoubtedly provide leads into both how 
NK cells develop as well as how developing NK cells figure into 
human host defense.
RTEL1
The third case of classic NKD, similarly to GATA2, is a case of 
a young girl who died of varicella infection at the age of 2 years. 
Originally reported in 2005 (60), her genetic lesion was recently 
solved by whole exome sequencing and found to be due to 
homozygous mutation in RTEL1 (61). Consistent with RTEL1 
being a cause of specific NKD, the girl had seemingly normal 
immunoglobulin levels and specific antibody titers, normal 
T  and B lymphocyte counts and subsets, and absence of bone 
marrow failure. Notably, however, she had severely decreased 
NK cell number and function that was not rescued by IL-2. As 
common γ chain and JAK3 mutations lead to SCID, her IL-15 
levels and signaling pathways were tested, yet were found to be 
intact (61). RTEL1 deficiency is a reported cause of Hoyeraal–
Hreidarsson Syndrome, an X-linked telomere deficiency 
prevalent among the Ashkenazi Jewish population that causes 
dyskeratosis congenita, bone marrow failure syndrome, and 
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immunodeficiency (62). The mutation reported in this (2-year-
old female) patient is a founder mutation causing Hoyeraal–
Hreidarsson syndrome and lymphopenia, including progressive 
NK cell immunodeficiency (63, 64). Interestingly, the patient 
had no clinical features of Hoyeraal–Hreidarsson syndrome, and 
her growth and neurological development were normal for her 
age (personal communication, A. Etzioni, 2016). She did have 
an inverted CD4/CD8 T cell ratio but was virally infected (61). 
The patient also did not have recognizable platelet abnormalities 
or anemia (personal communication, A. Etzioni, 2016). Since 
the discovery of this patient, there have not been other reports 
of biallelic RTEL1 mutations causing selective NKD. However, 
given the molecular mechanism of MCM4 deficiency, the link 
between RTEL1, which also plays a role in DNA repair, and NK 
cell development is interesting. As the patient was deceased at the 
time of genetic study, unfortunately in-depth studies of NK cell 
subsets or developmental processes were not tenable. The effect 
of RTEL1 deficiency on NK cell development underscores the 
specific sensitivity of human NK cells to DNA damage and the 
requirement for the DNA damage response in normal human 
NK cell development and homeostasis.
IRF8
The most recent description of cNKD identifies the cause of NKD 
in a family first described in 1982 with severe EBV susceptibility 
and absent NK cell function in affected individuals (65). The lon-
gitudinal study of a surviving affected sibling shows a distinctive, 
stable NK cell phenotype, with decreased NK cell function and 
increased CD56bright NK cells relative to the CD56dim subset (66). 
This phenotype is conserved in other patients with biallelic IRF8 
mutation and is NK cell intrinsic. Gene expression analysis of NK 
cells from the proband shows deregulation of genes involved in 
NK cell maturation and effector function, suggesting that IRF8 
is playing a role in the regulation of genes that include NFIL3, 
PRDM1, TBX21, GRZB, STAT5a, STAT5b, and PRF. Strikingly, 
a similar block in terminal maturation is also observed in mice 
with homozygous, but not heterozygous Irf8 mutations. IRF8 
deficiency as a result of both homozygous and heterozygous 
mutation can lead to DC deficiency (67, 68), although DC subsets 
in the proband reported here were only minimally affected (66). 
While mutation and gene dosage effects may be at play, the NK 
cell phenotype was conserved between all patients with biallelic 
IRF8 mutations studied but was not identified in any individuals 
with heterozygous IRF8 mutation. These findings demonstrate a 
requirement for IRF8 in terminal NK cell maturation and human 
antiviral defense and identify biallelic mutations in IRF8 as a 
newly described cause of cNKD.
FUNCTiONAL NKD
In contrast to cNKD, functional NKD (fNKD) represents a sce-
nario in which NK cells are present in normal numbers but have 
some impaired functional capacity. In fNKD, a patient’s NK cells 
appear to have gone through appropriate developmental progres-
sion and are not unduly susceptible to cell death (i.e., impaired 
survival). This distinction makes this category particularly 
difficult to diagnose clinically as the most common screening 
tests of quantitative flow cytometry will most likely be normal. 
Thus, a suspicion given a patient’s particular clinical susceptibility 
is necessary to prompt a more substantive assessment of NK cell 
function. While presently fewer in number, it is possible that the 
fNKD category may ultimately outweigh the cNKD category in 
number of mechanistically defined diagnoses. Presently, there is 
only one known fNKD that is caused by biallelic specific muta-
tions in FCGR3A.
FCGR3A
The only cause of fNKD reported to date is a rare mutation in 
FCGR3A (OMIM #615705), the gene encoding the low affinity 
IgG Fc receptor found on NK cells and macrophages (FcγRIIIA, 
CD16). Originally reported as the first monogenic cause of 
isolated NKD (69, 70), the c.230T-A transversion leads to L66H 
substitution in the first extracellular Ig domain of CD16 and 
is disease-causing when homozygous (69–71). Notably, while 
protein is expressed, the L66H substitution leads to loss of 
recognition of CD16 by mAb B73.1 while retaining recognition 
by the more commonly used 3G8 mAb (71). Therefore, dual 
detection with these antibodies is a rapid screen for this rare 
mutation as in certain individuals the B73.1 epitope will not 
be detected, although genotyping is required to confirm this 
molecular diagnosis (as individuals have been identified lack-
ing the epitope for other reasons). Aside from the apparent loss 
of CD16+ NK cells if using mAb B73.1, NK cells from these 
patients appear to have appropriate development and subset 
generation (71).
This cause of fNKD was first identified in two patients with 
recurrent frequent upper respiratory infections and recurrent 
HSV (as well as herpes whitlow in one patient and recurrent 
varicella zoster in the second) (69, 70). Our group subsequently 
identified homozygous L66H substitution in a 14-year-old male 
with recurrent EBV-driven Castleman’s disease and recalcitrant 
cutaneous warts (71). While CD16 function is required to 
mediate ADCC, strikingly the patients with CD16 L66H muta-
tion have normal ADCC-mediated cellular cytotoxicity, yet 
impaired natural cytotoxicity. This seemingly paradoxical effect 
is explained by the location of the mutation in the membrane 
distal Ig-like domain, which does not affect binding to IgG Fc 
mediated by the membrane proximal domain. Instead, molecular 
studies of the effect of L66H mutation revealed a role for the distal 
Ig-like domain of CD16 in binding to and stabilizing the NK cell 
coactivating receptor CD2, thus delineating a crucial role for 
CD16 in the co-stimulation of natural cytotoxicity in addition 
to its well-defined role in ADCC (71). Recently, the biology of 
this interaction has been further advanced through the study 
of individuals who do not possess the NKG2C locus in which 
a compensatory co-stimulatory relationship between CD2 and 
CD16 were demonstrated to be of value (72). Thus while, only one 
example of fNKD, this disorder has provided valuable insights 
into how NK cells react to challenges and focus upon patients 
with abnormal NK cell function, but grossly normal appearing 
NK cells should lead to important new leads both biologically 
and clinically.
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PUTTiNG iT ALL iN CONTeXT
While originally classified as classical or functional, the lines 
between the types of NK cell deficiencies has been blurred by 
increased resolution of NK cell subsets as well as the norma-
tive ranges and diversity of human NK cells (5, 23, 24). This 
is exemplified by the example of GATA2 mutation, which 
was initially reported as leading to absence of circulating NK 
cells but which, upon careful analysis was shown to lead to 
decreased NK cell number, specifically loss of the CD56bright NK 
cell subset, accompanied by decreased function (33). Thus, it is 
possible to have a scenario in which NK cells may be present by 
clinical enumeration in a patient with classical NKD. The use 
of multiparametric flow cytometry to evaluate even the most 
rudimentary of NK cell subsets provides invaluable insight into 
the potential source of NKD. This is particularly true of GATA2 
deficiency, which has a distinctive and seemingly immutable 
phenotype with regards to the absence of CD56bright NK cells 
(33, 37, 38).
A fascinating biological question has emerged from these dis-
coveries of NKD, namely that of the interdependence of subsets 
upon each other for function, as well as the relative importance 
of NK cell number versus functional potential. Particularly in the 
case of GATA2 and MCM4, the skewing of CD56bright and CD56dim 
subset generation has a seemingly profound effect on the function 
of the other subset (33, 53). Namely, in cases where CD56dim NK 
cells are present in GATA2 patients, these cells remain unable to 
mediate the contact-dependent target cell lysis that is a functional 
hallmark of the CD56dim subset. In the case of MCM4 deficiency, 
although it seems that the CD56bright subset is impacted more so 
than the CD56dim subset, profoundly decreased NK cell func-
tion by the CD56dim subset is a likely a contributing cause of the 
patients’ disease (54).
These observations add to an interesting but complicated 
literature on the ontology of human NK cells and ultimately 
speak to the need for a better understanding of the mechanism 
of, and requirement for human NK cell development. Finally, 
the question of the relationship between NK cell number, subset 
distribution, function, and disease state remains incompletely 
understood. Whether it is more advantageous to have fewer NK 
cells that are appropriately developed, as opposed to a greater 
number of inappropriately mature cells, remains to be seen. 
The evidence points to the former, begging the analogy that it 
is more important to have a small, functional team than a large 
one with badly behaved players. By extension, a small team may 
be a result of a disruptive individual, so determining the relative 
contribution of the deregulation of function and/or phenotype 
will be increasingly insightful into the pathogenesis of NKD. 
Emerging evidence in transplantation for primary immunode-
ficiency emphasizes this point, as having potentially very low 
numbers of NK cells that have the potential to work effectively 
may suffice at the right time and under the right circumstance. 
Along these lines, it is even possible that having a few defec-
tive NK cells could be more damaging than having none at all. 
Answering these questions will require further studies that care-
fully and thoughtfully dissect human NK cell development in 
health and disease. Furthermore, there are likely to be context-, 
time-, and exposure-specific components of NKD as there are 
likely to be critical windows in which an absence of NK cell 
subsets or functions may be particularly relevant for human 
host defense.
It should also be noted that all these studies in NKD will 
benefit from a greater understanding of NK cells within unique 
microenvironments. By necessity, most of this work has used 
peripheral blood as the source of NK cells, yet the tissue-specific 
NK cell phenotypes in liver, gravid uterus, and secondary lym-
phoid tissue speak to their shaping by these sites. Understanding 
how these seldom-visualized cells are affected by disease will 
be an important component of a greater understanding of the 
non-redundant function of human NK cells in health and disease. 
The present state of knowledge, however, suggests that there are 
patients with deficiencies of immunity reflected primarily within 
the NK cell compartment who are in need of mechanistic and 
therapeutic answers. Further study into individuals with sugges-
tive phenotypes will likely produce new causative genes for NKD 
and insights into NK cell biology that can ultimately lead to new 
and improved therapeutic directions.
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